Failed Republican reformers left hoping for Obamacare failure

19 July 2017

The latest Republican attempts to replace or repeal the Affordable Care Act – former President Barack Obama’s signature policy that is nicknamed Obamacare – have gone the way of those before them, ending in failure.

On Monday night, two Republican senators said that they could not support the latest version of the healthcare bill proposed by Senate majority leader Mitch McConnell to replace Obamacare, meaning he was short of the votes needed to pass it.

This prompted a change of tack, with the Trump administration deciding instead that it would be better to simply focus on repealing Obamacare and come up with a replacement later. But this approach also floundered on Tuesday when three Republican senators said that they would oppose that approach, one saying that she would not repeal Obamacare ‘without a replacement that addresses my concerns’.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK